BaseLaunch announces a new partnership with AbbVie

Further strengthens BaseLaunch's global pharma industry partnerships

Pigeon Singapore, LyondellBasell collaborate to incorporate bio-circular plastic in nursing bottles

The LyondellBasell CirculenRenew polymers are made from renewable feedstocks derived from bio-based wastes

LyondellBasell awarded the 2023 Global Medical Plastics Company of the year

LyondellBasell is among the top three global polyolefin manufacturers in terms of capacity and sustainable solutions

M. Holland join hands with LyondellBasell to distribute purell medical grade resins

New material distribution will serve medical device and pharmaceutical packaging manufacturers.

AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension

The medicine was well tolerated, with no unexpected safety issue

Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

argenx reports positive phase 3 ADAPT SERON results of VYVGART in AChR-Ab seronegative gMG

VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications

AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib

The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study

AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata

The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage

Suven Life Sciences announces first patient randomized in Phase-2b clinical trial of Ropanicant

There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated